Workflow
鑫元科创AI指数发起式
icon
Search documents
鑫元基金旗下4只基金增聘莫志刚
Zhong Guo Jing Ji Wang· 2026-02-11 08:05
中国经济网北京2月11日讯今日,鑫元基金公告,鑫元科创AI指数发起式、鑫元中证800红利低波动ETF 联接、鑫元中证800自由现金流指数、鑫元中证800红利低波动ETF增聘莫志刚。 莫志刚历任万家基金管理有限公司量化研究员,南华基金管理有限公司基金经理助理、基金经理,西藏 东财基金管理有限公司基金经理,华夏理财有限责任公司投资经理。2025年5月加入鑫元基金管理有限 公司,历任基金经理助理。 | 基金名称 | 鑫元上证科创板人工智能指数型发起式证券投资基金 | | --- | --- | | 基金简称 | 鑫元科创 AI 指数发起式 | | 基金主代码 | 024409 | | 基金管理人名称 | 鑫元基金管理有限公司 | | 公告依据 | 《证券基金经营机构董事、监事、高级管理人员及从业人员监督管 | | | 理办法》、《公开募集证券投资基金信息披露管理办法》、《证券期货 | | | 经营机构投资管理人员注册登记规则》等, | | 基金经理变更类型 | 增聘基金经理 | | 新任基金经理姓名 | 莫志刚 | | 共同管理本基金的其他基 | 刘宇涛 | | 金经理姓名 | | | 基金名称 | 鑫元中证 80 ...
权益类基金发行、成立、建仓全链条提速
Zheng Quan Ri Bao· 2025-08-20 16:44
Core Viewpoint - The A-share market has shown strong performance, leading to increased investor confidence and accelerated fundraising activities in equity funds [1][3]. Group 1: Fundraising and Market Activity - Multiple equity funds have completed fundraising ahead of schedule, indicating high investor demand, with some funds raising their target amounts in just one day [2][3]. - The recent trend shows that over 60 equity funds have been established since August, with many new funds experiencing significant net asset value (NAV) growth shortly after inception [3][4]. Group 2: Fund Management and Investment Strategy - Fund managers are actively increasing their equity positions, with average stock holdings reaching high levels; ordinary equity funds have an average equity position of approximately 91.41% [4]. - The rapid deployment of capital by fund managers reflects a positive outlook on market conditions, which is expected to attract more incremental funds into the equity market [4]. Group 3: Market Outlook and Sector Focus - The market is currently driven by increased liquidity, with a preference for technology and small-cap stocks expected to outperform in the short term [5]. - Future investment strategies should focus on sectors with positive fundamental changes driven by policy, particularly technology, consumption, high-end manufacturing, and pharmaceuticals [6].